Publications
664 results found
Myerson JS, Nimako K, Moore S, et al., 2011, QUALITY OF LIFE ASSESSMENTS IN LUNG CANCER AND MESOTHELIOMA. A COMPARISON OF QUESTIONNAIRES AND PHYSICIAN CONSULTATION - A POOR WORKMAN ALWAYS BLAMES HIS TOOLS?, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S1206-S1207, ISSN: 1556-0864
Myerson JS, Nimako K, Ranu H, et al., 2011, RANDOMISED EVALUATION OF STENTS TO OPEN RESTRICTED AIRWAYS IN PATIENTS WITH CENTRALLY PLACED NON-SMALL CELL LUNG CANCER (RESTORE - AIR), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S1201-S1202, ISSN: 1556-0864
Khor KS, Tai D, Popat S, et al., 2011, Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol: 29, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Khor KS, Tai D, Popat S, et al., 2011, Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer., J Clin Oncol, Vol: 29
7011 Background: The benefit of chemotherapy after surgery for lung cancer is established, but roles and responsibilities of discussing adjuvant chemotherapy are not established. Whilst risks are straight forward to convey, difficulties in conveying the benefit results from published hazard ratios as the benefit varies with stage and therefore needs to be calculated individually and conveyed in a language that is understood by the patient. METHODS: From 2010 to 2011, a survey was conducted of cancer physicians, oncologists and surgeons in the UK. Clinicians asked to rank the most appropriate speciality to discuss adjuvant chemotherapy with patients, to calculate expected survival given baseline survival probability of 80% and a hazard ratio of 0.80, and then surveyed for the additional expected gain in cohorts with a 5 year survival probability of 40%, 60% and 80% respectively before they would recommend adjuvant chemotherapy Results: A total of 202 responses were received from 27 surgeons, 77 physicians, 87 oncologists (11 unstated). The majority of 56% of surgeons, 79% of physicians and 61% of oncologists felt an oncologist as the most appropriate initial clinician to discuss adjuvant chemotherapy with patients after surgery. In total 33% of surgeons, 53% of physicians and 73% of oncologists were able to correctly calculate the expected survival of patients. When asked about perceived value before considering recommending adjuvant chemotherapy with 5 year survival probabilities of 40%, 60% and 80%, clinicians reported an expected a mean gain (SE) of 20.8% (2.7), 15.6% (2.4) and 13.2% (2.1) against an expected of 12%, 8% and 4% respectively with a hazard ratio of 0.80. CONCLUSIONS: Our survey suggest oncologists as the clinicians best able to calculate the individual benefit of adjuvant chemotherapy and the majority of specialities polled agreed oncologists as the most appropriate initial person to discuss adjuvant chemotherapy with patients after radical surgery f
Zhao D-B, Chandler I, Chen Z-M, et al., 2011, Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor β receptor type II as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysis, CHINESE MEDICAL JOURNAL, Vol: 124, Pages: 483-490, ISSN: 0366-6999
- Author Web Link
- Cite
- Citations: 6
Okera M, Chan S, Dernede U, et al., 2011, A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings, BRITISH JOURNAL OF CANCER, Vol: 104, Pages: 407-412, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 13
O'Connor SJ, Elliott S, Chinegwundoh J, et al., 2011, Retrospective audit of a district general hospital (DGH) lung multi-disciplinary team (MDT) - lessons from misses and near-misses of treatment deadline, Publisher: ELSEVIER IRELAND LTD, Pages: S23-S23, ISSN: 0169-5002
Trani L, Myerson J, Ashley S, et al., 2010, Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations, LUNG CANCER, Vol: 70, Pages: 200-204, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 3
Myerson JS, Faria A, Puglisi M, et al., 2010, The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer, LUNG CANCER, Vol: 69, Pages: 365-366, ISSN: 0169-5002
Brunetto AT, Carden CP, Myerson J, et al., 2010, Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy, JOURNAL OF THORACIC ONCOLOGY, Vol: 5, Pages: 1397-1403, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 17
Myerson JS, Iqbal SA, O'Brien MER, et al., 2010, Supersensitive Mutation: Two Case Reports of Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, CLINICAL LUNG CANCER, Vol: 11, Pages: E5-E8, ISSN: 1525-7304
- Author Web Link
- Cite
- Citations: 2
Benson C, Kristeleit RS, Ashley S, et al., 2010, Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Irshad S, Popat S, Shah RN, et al., 2010, A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using <SUP>18</SUP>fdg-PET, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 4
Calderone RG, Nimako K, Leary AN, et al., 2010, USE OF ZOLEDRONIC ACID IN LUNG CANCER, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S99-S100, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 4
Nicholson AG, Gonzalez D, Shah P, et al., 2010, Refining the Diagnosis and <i>EGFR</i> Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and <i>EGFR</i> Mutation Analysis, JOURNAL OF THORACIC ONCOLOGY, Vol: 5, Pages: 436-441, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 168
Forster M, Enting D, Nicholson AG, et al., 2010, The combination of Young's syndrome and small cell lung cancer-A spiky connection?, LUNG CANCER, Vol: 67, Pages: 372-375, ISSN: 0169-5002
Puglisi M, Dolly S, Faria A, et al., 2010, Treatment options for small cell lung cancer - do we have more choice?, BRITISH JOURNAL OF CANCER, Vol: 102, Pages: 629-638, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 81
Hubner R, Goldstein R, Mitchell S, et al., 2010, Influence of co-morbidity on renal function estimation by Cockcroft-Gault calculation in lung cancer and mesotheliorna patients receiving platinum-based chemotherapy, Publisher: ELSEVIER IRELAND LTD, Pages: S9-S9, ISSN: 0169-5002
Goldstein R, Reid F, Campbell J, et al., 2010, Neurosurgery for brain metastases (BM) in the management of non-small cell lung cancer (NSCLC): A retrospective study of all cerebral metastasectornies at St George's Hospital London (SGH), 1999-2009, Publisher: ELSEVIER IRELAND LTD, Pages: S38-S38, ISSN: 0169-5002
Hubner R, Goldstein R, Mitchell S, et al., 2010, Influence of co-morbidity on renal function estimation by Cockcroft Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy, Lung Cancer, Vol: 67, Pages: S9-S9, ISSN: 0169-5002
Faivre-Finn C, Kerr K, Macfie A, et al., 2010, Guidelines on the radical management of patients with lung cancer, Thorax
Myerson JS, Moore SA, Popat S, et al., 2010, Quality of Life Assessments in Lung Cancer - An evaluation of three questionnaires. What's best for routine clinical practice?, Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Dolly SO, Popat S, 2009, Endocrine manifestations of malignancy, Medicine, Vol: 37, Pages: 457-460, ISSN: 1357-3039
Endocrine manifestations of cancer are primarily observed as paraneoplastic syndromes. These are rare systemic manifestations of malignancy due to non-size-related effects of the underlying cancer. The pathobiology of these syndromes is due to underlying production of hormones and related substances that act in an endocrine or paracrine manner on effector cells distributed through the body, thereby resulting in systemic manifestations. Two major mechanisms are observed: ectopic hormone production by tumours not involving endocrine organs, and malignancy of endocrine glands resulting in direct secretion of hormones. The most common paraneoplastic syndromes observed are hypercalcaemia of malignancy, Cushing's syndrome and the syndrome of inappropriate antidiuretic hormone, each of which may be the primary presenting feature of the underlying malignancy. Rarer syndromes result from ectopic production of less frequently observed bioactive proteins, e.g. growth hormone releasing hormone, human chorionic gonadotrophin, insulin-like growth factors, renin and vasoactive intestinal peptide. In this article we overview the spectrum of common and rare paraneoplastic syndromes observed and their manifestations. © 2009 Elsevier Ltd. All rights reserved.
Faria A, Myerson JS, Puglisi M, et al., 2009, The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients, 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Publisher: PERGAMON-ELSEVIER SCIENCE LTD, Pages: 523-524, ISSN: 1359-6349
O'Brien ME, Myerson JS, Popat S, et al., 2009, The use of PET-CT scan in the assessment of response to Tarceva (erlotinib) in non small cell lung (NSCLC) cancer patients, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S390-S391, ISSN: 1556-0864
Trani L, Myerson J, Young K, et al., 2009, 9054 Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations, European Journal of Cancer Supplements, Vol: 7, Pages: 521-521, ISSN: 1359-6349
Trani L, Myerson J, Young K, et al., 2009, Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations, 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Publisher: PERGAMON-ELSEVIER SCIENCE LTD, Pages: 521-521, ISSN: 1359-6349
Bole C, Jayaprakash V, Platek M, et al., 2009, COFFEE AND TEA CONSUMPTION AND RISK OF HEAD AND NECK CANCERS, 42nd Annual Meeting of the Society-for-Epidemiologic-Research, Publisher: OXFORD UNIV PRESS INC, Pages: S49-S49, ISSN: 0002-9262
Cohan DM, Popat S, Kaplan SE, et al., 2009, Oropharyngeal cancer: current understanding and management, CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, Vol: 17, Pages: 88-94, ISSN: 1068-9508
- Author Web Link
- Cite
- Citations: 95
Benning J, Starling N, Myerson JS, et al., 2009, An audit of neutropaenia in patients with small cell lung carcinoma (SCLC) undergoing platinum-based chemotherapy - urgent need for specific SCLC guidelines, Publisher: ELSEVIER IRELAND LTD, Pages: S13-S13, ISSN: 0169-5002
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.